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Introduction
About 90% of all cancer deaths are influenced by the appearance, at
some point in the evolution of this disease, of tumor resistance to
cytostatic treatments, so the magnitude of this problem is considerable,
since cancer is one of the leading causes of mortality.
There are tumors with natural resistance to cytostatics, and others that
despite being sensitive to the start of treatment, progressively become
refractory, that is to say, they acquire resistance.
In addition, tumor cells can simultaneously acquire resistance against a
diverse group of drugs. This phenomenon is called pleotropic
resistance or multidrug resistance. This mechanism could explain the
tumor resistance observed in chemotherapy treatments with multiple
agents.
Objectives
The aim of this work is to study possible mechanisms of cross resistance
between Cisplatin and Bleomycin in Saccharomyces cerevisiae.
Methodology
The Yeast strain and culture medium
The experiments were carried out with the haploid yeast
strain Saccharomyces cerevisiae WS8105-1C (genotype:
MATalpha, ade2, arg4-17, trp1-289, ura3-52), with the
resistant haploid yeast strain to cisplatin Saccharomyces
cerevisiae WS8105-1C-R300cisPt and with the resistant
haploid yeast strain to bleomycin Saccharomyces cerevisiae
WS8105-1C-R 0.158 Bleo. Yeast cells were grown in a solid
medium of YPD (1 % Bacto-yeast extract, 2 % Bacto-
peptone, 2 % dextrose and 2 % Bacto-agar) for the
cytotoxicity assay.
Chemicals
The antineoplastic drugs used were cisplatin and bleomycin.
The doses used were 0, 1, 10, 50, 100, 300, 500, 700 and
900 μg/ml of cisplatin and, 0, 0.001, 0.003, 0.005, 0.008,
0.01, 0.03, 0.05 and 0.06 UI/ml of bleomycin.
Experimental protocol
Cytotoxicity test: Prior to exposures, wild yeast cells were
cultured during five days on YPD-agar plates at 30°C and
then a loop was suspended in 1000 μl of sterile water at a
titer of 2E+7 cells/ml. This quantity of cells was added to test
tubes with different doses of cisplatin and they were
completed with sterile water until 1000 μl. Then, the tubes
were cultured during 24 hours at 30°C and cells washed
twice with sterile water. For drop test assay, six 10-fold serial
dilutions from each sample were prepared and five-microliter
aliquots of each dilution were spotted onto YPD plates. The
same cytotoxicity test was carried out but using bleomycin.
In order to evaluate if there were mechanisms of cross-
resistance, the following protocol was performed.
On the one hand, 2E+7 cells/ml of resistant yeast strain to
cisplatin WS8105-1C-R300cisPt were added to test tubes
with the different doses of bleomycin; and on the other hand,
2E+7 cells/ml of resistant yeast strain to bleomycin
WS8105-1C-R 0.158 Bleo were added to test tubes with the
different doses of cisplatin. The test tubes were completed
with sterile water until 1000 μl. Then, the tubes were cultured
during 24 hours at 30°C and cells washed twice with sterile
water. For drop test assay, six 10-fold serial dilutions from
each sample were prepared and five-microliter aliquots of
each dilution were spotted onto YPD plates.
Results and conclusions
An On the one hand, the cytotoxicity curve for bleomycin obtained by
drop test showed that the decrease of the surviving fraction in strain
WS8105-1C-R300cisPt was clearly greater than in the wild strain
after exposure to Bleomycin. The ID50 and ID90 values obtained
were 0.001 UI/ml and 0.158 UI/ml, respectively, in the wild strain
and, 0.00054 IU/ml of Bleomycin (1.85 times more sensitive with
respect to the wild strain) and 0.00097 IU/ml of Bleomycin (162.89
times more sensitive with respect to the wild strain).
On the other hand, the cytotoxicity curve for cisplatin obtained by
drop test allowed to calculate the ID50 and ID90 values, obtaining 90
μg/ml and 300 μg /ml, respectively, in the wild strain and, 42 μg /ml
of cisplatin (2,14 times more sensitive with respect to the wild strain)
and 1384 μg /ml of cisplatin (5,24 times more resistant with respect
to the wild strain), in the WS8105-1C-R 0.158 Bleo strain.
There were not statistically significant differences between the strain
studies and doses of drugs.
In conclusion, no cross resistance between cisplatin and bleomycin was
obtained in strains resistant to these cytostatic agents in S. cerevisiae.
Further studies are needed to clarify the absent of cross resistance in
tumoral cells.
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